(NASDAQ: CING) Cingulate's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.68%.
Cingulate's earnings in 2026 is -$28,796,325.On average, 8 Wall Street analysts forecast CING's earnings for 2026 to be -$34,026,419, with the lowest CING earnings forecast at -$39,902,771, and the highest CING earnings forecast at -$31,148,591. On average, 8 Wall Street analysts forecast CING's earnings for 2027 to be -$23,406,523, with the lowest CING earnings forecast at -$30,782,137, and the highest CING earnings forecast at -$15,574,296.
In 2028, CING is forecast to generate -$17,354,215 in earnings, with the lowest earnings forecast at -$18,811,306 and the highest earnings forecast at -$15,574,296.